Aia Group LTD Amgen Inc Transaction History

Aia Group LTD

$3.28 Billion
Q2 2024

A detailed history of Aia Group LTD transactions in Amgen Inc stock. As of the latest transaction made, Aia Group LTD holds 1,645 shares of AMGN stock, worth $519,820. This represents 0.02% of its overall portfolio holdings.

Number of Shares

1,645

Previous 2,153 23.59%

Holding current value

$519,820

Previous $612,000 16.18%

% of portfolio

0.02%

Previous 0.02%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 31, 2024	SELL	$262.75 - $319.31 $133,477 - $162,209	-508 Reduced 23.59%	1,645 $513,000
Q1 2024 May 06, 2024	BUY	$268.87 - $324.56 $578,877 - $698,777	2,153 New	2,153 $612,000
Q1 2023 Apr 28, 2023	SELL	$225.79 - $275.2 $284,721 - $347,027	-1,261 Reduced 12.96%	8,469 $2.05 Million
Q4 2022 Jan 31, 2023	BUY	$229.03 - $291.01 $1.22 Million - $1.55 Million	5,343 Added 121.79%	9,730 $2.56 Million
Q3 2022 Nov 04, 2022	SELL	$224.46 - $253.15 $606,939 - $684,517	-2,704 Reduced 38.13%	4,387 $989,000
Q2 2022 Aug 11, 2022	BUY	$230.71 - $256.74 $958,138 - $1.07 Million	4,153 Added 141.35%	7,091 $1.73 Million
Q1 2022 May 06, 2022	BUY	$219.27 - $242.57 $185,283 - $204,971	845 Added 40.37%	2,938 $710,000
Q4 2021 Feb 11, 2022	BUY	$198.88 - $227.6 $66,028 - $75,563	332 Added 18.85%	2,093 $471,000
Q3 2021 Nov 05, 2021	SELL	$212.27 - $248.7 $849 - $994	-4 Reduced 0.23%	1,761 $374,000
Q2 2021 Aug 03, 2021	SELL	$233.58 - $259.14 $156,265 - $173,364	-669 Reduced 27.49%	1,765 $435,000
Q1 2021 May 14, 2021	BUY	$221.91 - $258.6 $178,859 - $208,431	806 Added 49.51%	2,434 $606,000
Q4 2020 Feb 12, 2021	BUY	$216.38 - $257.67 $352,266 - $419,486	1,628 New	1,628 $386,000

Others Institutions Holding AMGN

# of Institutions

3,073

Shares Held

417M

Call Options Held

7.19M

Put Options Held

6.28M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $169B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Aia Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Aia Group LTD with notifications on news.

Account